Turning Point Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
267
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3.51B
Turning Point Therapeutics General Information
Description
Developer of oncology drug compounds dedicated to bringing differentiated therapies to patients with cancer. The company focuses on developing targeted therapies for oncogenic drivers and resistant mutations, thereby addressing unmet medical needs and improving treatment outcomes.
Contact Information
Website
www.tptherapeutics.comCorporate Office
- 10628 Science Center Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 10628 Science Center Drive
- Suite 200
- San Diego, CA 92121
- United States
Turning Point Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 17-Aug-2022 | $3.51B | Completed | Generating Revenue | ||
| 6. IPO | 17-Apr-2019 | Completed | Clinical Trials - General | |||
| 5. Mezzanine | 19-Oct-2018 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 01-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series C1) | 17-May-2017 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series B) | 16-Oct-2015 | $18M | $21.5M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 02-Jan-2014 | $3.5M | $3.5M | Completed | Startup |
Turning Point Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 7,404,248 | $0.000100 | 5% | $0.47 | $0.47 | 1x | $0.47 | 13.73% |
Turning Point Therapeutics Comparisons
Industry
Financing
Details
Turning Point Therapeutics Competitors (101)
One of Turning Point Therapeutics’s 101 competitors is Anaveon, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Anaveon | Venture Capital-Backed | Basel, Switzerland | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Oxford Biotherapeutics | Private Equity-Backed | Oxford, United Kingdom | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Mabworks Biotech | Venture Capital-Backed | Beijing, China |
Turning Point Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Turning Point Therapeutics Patents
Turning Point Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260159526-A1 | Crystalline forms of a macrocyclic compound | Pending | 19-Apr-2024 | ||
| WO-2023060022-A1 | Synthesis of macrocyclic compounds | Inactive | 05-Oct-2021 | ||
| US-20250002505-A1 | Synthesis of macroyclic compounds | Pending | 05-Oct-2021 | ||
| JP-2023515687-A | Therapeutic use of macrocycles | Pending | 02-Mar-2020 | ||
| AU-2021229457-A1 | Therapeutic uses of macrocyclic compounds | Inactive | 02-Mar-2020 | C07D498/18 |
Turning Point Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Turning Point Therapeutics Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brightway Future Capital | Venture Capital | Minority | ||
| CRCM Ventures | Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Foresite Capital | Growth/Expansion | Minority | ||
| HBM Healthcare Investments | Venture Capital | Minority |
Turning Point Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
14.68 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Turning Point Therapeutics FAQs
-
When was Turning Point Therapeutics founded?
Turning Point Therapeutics was founded in 2013.
-
Where is Turning Point Therapeutics headquartered?
Turning Point Therapeutics is headquartered in San Diego, CA.
-
What is the size of Turning Point Therapeutics?
Turning Point Therapeutics has 267 total employees.
-
What industry is Turning Point Therapeutics in?
Turning Point Therapeutics’s primary industry is Drug Discovery.
-
Is Turning Point Therapeutics a private or public company?
Turning Point Therapeutics is a Private company.
-
What is the current valuation of Turning Point Therapeutics?
The current valuation of Turning Point Therapeutics is .
-
What is Turning Point Therapeutics’s current revenue?
The current revenue for Turning Point Therapeutics is .
-
How much funding has Turning Point Therapeutics raised over time?
Turning Point Therapeutics has raised $323M.
-
Who are Turning Point Therapeutics’s investors?
Brightway Future Capital, CRCM Ventures, Cormorant Asset Management, Foresite Capital, and HBM Healthcare Investments are 5 of 15 investors who have invested in Turning Point Therapeutics.
-
Who are Turning Point Therapeutics’s competitors?
Anaveon, Centrose, Oxford Biotherapeutics, Sangamo Therapeutics, and Mabworks Biotech are some of the 101 competitors of Turning Point Therapeutics.
-
When was Turning Point Therapeutics acquired?
Turning Point Therapeutics was acquired on 17-Aug-2022.
-
Who acquired Turning Point Therapeutics?
Turning Point Therapeutics was acquired by Bristol-Myers Squibb.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
